Advertisement

Drugs

, Volume 79, Issue 15, pp 1697–1707 | Cite as

Emicizumab: A Review in Haemophilia A

  • Hannah A. BlairEmail author
Adis Drug Evaluation

Abstract

Emicizumab (Hemlibra®), a recombinant, humanized, bispecific monoclonal antibody, restores the function of missing activated factor VIII (FVIII) by bridging FIXa and FX to facilitate effective haemostasis in patients with haemophilia A. Subcutaneous emicizumab is approved in several countries, including in the USA and Japan, for the routine prophylaxis of bleeding episodes in patients with haemophilia A with or without FVIII inhibitors. It is also approved in the EU for the routine prophylaxis of bleeding episodes in patients with haemophilia A with inhibitors or severe haemophilia A without inhibitors. In phase III clinical trials, emicizumab prophylaxis significantly reduced annualized bleeding rates compared with no prophylaxis in adolescents and adults with haemophilia A with or without inhibitors, and prevented or substantially reduced bleeding in children with haemophilia A with or without inhibitors. Emicizumab was also associated with beneficial effects on health-related quality of life and health status, and was generally well tolerated. In view of its convenient route of administration and versatile dosage regimens (maintenance dose of once every 1, 2 or 4 weeks), emicizumab provides an effective and generally well-tolerated alternative to conventional FVIII replacement products for the prophylaxis of bleeding episodes in patients with haemophilia A, regardless of the presence or absence of inhibitors.

Notes

Acknowledgements

During the review process, the manufacturer of emicizumab was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Compliance with Ethical Standards

Conflict of interest

Hannah Blair is a salaried employee of Adis International Ltd/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.

Funding

The preparation of this review was not supported by any external funding.

References

  1. 1.
    Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1–47.CrossRefPubMedGoogle Scholar
  2. 2.
    Pelland-Marcotte MC, Carcao MD. Hemophilia in a changing treatment landscape. Hematol Oncol Clin North Am. 2019;33(3):409–23.CrossRefPubMedGoogle Scholar
  3. 3.
    Ljung R, Auerswald G, Benson G, et al. Inhibitors in haemophilia A and B: management of bleeds, inhibitor eradication and strategies for difficult-to-treat patients. Eur J Haematol. 2019;102(2):111–22.CrossRefPubMedGoogle Scholar
  4. 4.
    Genentech Inc. Hemlibra® (emicizumab-kxwh) injection, for subcutaneous use: US prescribing information. 2018. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2483adba-fab6-4d1b-96c5-c195577ed071. Accessed 9 Sept 2019.
  5. 5.
    Chugai Pharmaceutical Co Ltd. Chugai’s Hemlibra® subcutaneous injection receives approval for hemophilia A without inhibitors and extension of dosing interval [media release]. 21 Dec 2018. http://www.chugai-pharm.co.jp/english/news/detail/20181221153002_580.html.
  6. 6.
    Roche. Hemlibra solution for injection: summary of product characteristics. 2019. http://www.ema.europa.eu/en/documents/product-information/hemlibra-epar-product-information_en.pdf. Accessed 9 Sep 2019.
  7. 7.
    Kitazawa T, Esaki K, Tachibana T, et al. Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens. Thromb Haemost. 2017;117(7):1348–57.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Kitazawa T, Igawa T, Sampei Z, et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med. 2012;18(10):1570–4.CrossRefPubMedGoogle Scholar
  9. 9.
    Muto A, Yoshihashi K, Takeda M, et al. Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation. J Thromb Haemost. 2014;12(2):206–13.CrossRefPubMedGoogle Scholar
  10. 10.
    Muto A, Yoshihashi K, Takeda M, et al. Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A. Blood. 2014;124(20):3165–71.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Sampei Z, Igawa T, Soeda T, et al. Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PLoS One. 2013;8(2):e57479.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Ogiwara K, Horiuchi H, Nogami K, et al. Assessment of emicizumab-driven clot stability in hemophilia A model [abstract]. Blood. 2018;132(Suppl 1):2478.CrossRefGoogle Scholar
  13. 13.
    Shima M, Hanabusa H, Taki M, et al. Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A. N Engl J Med. 2016;374(21):2044–53.CrossRefPubMedGoogle Scholar
  14. 14.
    Shima M, Hanabusa H, Taki M, et al. Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors. Blood Adv. 2017;1(22):1891–9.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Uchida N, Sambe T, Yoneyama K, et al. A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects. Blood. 2016;127(13):1633–41.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Adamkewicz J, Schmitt C, Calatzis A, et al. Pharmacodynamic data and coagulation biomarkers in persons with hemophilia A (PwHA) with inhibitors: results from the HAVEN 1 emicizumab (ACE910) phase 3 study [abstract no. OC 47.1]. Res Pract Thromb Haemost. 2017;1(Suppl 1):162.Google Scholar
  17. 17.
    Kiialainen A, Schmitt C, Oldenburg J, et al. Pharmacokinetics and biomarkers in persons with haemophilia a (PwHA) without FVIII inhibitors receiving emicizumab once weekly in the phase 3 HAVEN 3 study [abstract no. P022]. Haemophilia. 2019;25(Suppl 1):46–7.Google Scholar
  18. 18.
    Kiialainen A, Schmitt C, Adamkewicz JI, et al. Pharmacokinetics and biomarkers in persons with haemophilia a (PwHA) receiving emicizumab every 2 or 4 weeks [abstract no. P021]. Haemophilia. 2019;25(Suppl 1):45–6.Google Scholar
  19. 19.
    Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377(9):809–18.CrossRefPubMedGoogle Scholar
  20. 20.
    Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med. 2018;379(9):811–22.CrossRefPubMedGoogle Scholar
  21. 21.
    Pipe S, Shima M, Lehle M, et al. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol. 2019;6(6):e295–305.CrossRefPubMedGoogle Scholar
  22. 22.
    Jimenez-Yuste V, Klamroth R, Castaman G, et al. A single-arm, multicentre, open-label, phase III clinical trial to evaluate the safety and tolerability of prophylactic emicizumab in persons with haemophilia A (PwHA) with FVIII inhibitors (STASEY): interim analysis results [abstract no. OC 60.3]. Res Pract Thromb Haemost. 2019;3(Suppl 1):116–7.Google Scholar
  23. 23.
    Young G, Liesner R, Sidonio RF Jr, et al. Emicizumab prophylaxis provides flexible and effective bleed control in children with hemophilia A with inhibitors: results from the HAVEN 2 study [abstract]. Blood. 2018;132(Suppl 1):632.CrossRefGoogle Scholar
  24. 24.
    Shima M, Nogami K, Nagami S, et al. Every 2 weeks or every 4 weeks subcutaneous injection of emicizumab in pediatric patients with severe hemophilia a without inhibitors: a multi-center, open-label study in Japan (HOHOEMI study) [abstract]. Blood. 2018;132(Suppl 1):1186.CrossRefGoogle Scholar
  25. 25.
    Callaghan MU, Kuebler PJ, Gao L, et al. Characterization of the impact of prior ITI on patient outcomes in HAVEN1 [abstract]. Am J Hematol. 2018;93(9):e10–1.Google Scholar
  26. 26.
    Mancuso ME, Oldenburg J, Callaghan M, et al. Emicizumab prophylaxis in adolescent/adult patients with haemophilia A previously receiving episodic or prophylactic bypassing agent treatment: updated analyses from the HAVEN 1 study [abstract no. BSH18-PO-146]. Br J Haematol. 2018;181(Suppl 1):127.Google Scholar
  27. 27.
    Oldenburg J, Mahlangu JN, Bujan W, et al. The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 study. Haemophilia. 2019;25(1):33–44.CrossRefPubMedGoogle Scholar
  28. 28.
    Skinner M, Negrier C, Paz-Priel I, et al. Emicizumab prophylaxis improves long-term physical health scores in persons with haemophilia A (PwHA) with and without inhibitors: update from the HAVEN 3 and HAVEN 4 studies [abstract no. PB0698]. Res Pract Thromb Haemost. 2019;3(Suppl 3):328–9.Google Scholar
  29. 29.
    Jimenez-Yuste V, Shima M, Paz-Priel I, et al. Preference for emicizumab over prior factor treatments: results from the HAVEN 3 and HAVEN 4 studies [abstract]. Blood. 2018;132(Suppl 1):1187.CrossRefGoogle Scholar
  30. 30.
    Mancuso ME, Mahlangu J, Sidonio RF, et al. Emicizumab prophylaxis in paediatric persons with haemophilia A (PWHA) with inhibitors: impact on health-related outcomes and caregiver burden in the HAVEN 2 study [abstract no. OR10]. Haemophilia. 2018;24(Suppl 1):28–9.Google Scholar
  31. 31.
    Santagostino E, Oldenburg J, Chang T, et al. Surgical experience from four phase III studies (HAVEN 1-4) of emicizumab in persons with haemophilia A (PwHA) with or without FVIII inhibitors [abstract no. OC 60.1]. Res Pract Thromb Haemost. 2019;3(Suppl 1):115.Google Scholar
  32. 32.
    Callaghan M, Negrier C, Paz-Priel I, et al. Emicizumab treatment is efficacious and well tolerated long term in persons with haemophilia A (PwHA) with or without FVIII inhibitors: pooled data from four HAVEN studies [abstract no. OC 60.2]. Res Pract Thromb Haemost. 2019;3(Suppl 1):116.Google Scholar
  33. 33.
    Levy GG, Asikanius E, Kuebler P, et al. Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: experience from the HAVEN clinical program. J Thromb Haemost. 2019.  https://doi.org/10.1111/jth.14491.CrossRefPubMedGoogle Scholar
  34. 34.
    Paz-Priel I, Chang T, Asikanius E, et al. Immunogenicity of emicizumab in people with hemophilia A (PwHA): results from the HAVEN 1-4 studies [abstract]. Blood. 2018;132(Suppl 1):633.CrossRefGoogle Scholar
  35. 35.
    Rocino A, Franchini M, Coppola A. Treatment and prevention of bleeds in haemophilia patients with inhibitors to factor VIII/IX. J Clin Med. 2017;6(4):46.CrossRefPubMedCentralGoogle Scholar
  36. 36.
    National Hemophilia Foundation. Recommendation on the use and management of emicizumab-kxwh (Hemlibra®) for hemophilia A with and without inhibitors. 2018. http://www.hemophilia.org. Accessed 9 Sept 2019.
  37. 37.
    Collins PW, Liesner R, Makris M, et al. Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving emicizumab. Interim guidance from UKHCDO inhibitor working party and executive committee. Haemophilia. 2018;24(3):344–7.CrossRefPubMedGoogle Scholar
  38. 38.
    Scott LJ, Kim ES. Emicizumab-kxwh: first global approval. Drugs. 2018;78(2):269–74.CrossRefPubMedGoogle Scholar
  39. 39.
    Cassis FR, Querol F, Forsyth A, et al. Psychosocial aspects of haemophilia: a systematic review of methodologies and findings. Haemophilia. 2012;18(3):e101–14.CrossRefPubMedGoogle Scholar
  40. 40.
    Coppola A, Cerbone AM, Mancuso G, et al. Confronting the psychological burden of haemophilia. Haemophilia. 2011;17(1):21–7.CrossRefPubMedGoogle Scholar
  41. 41.
    Nogami K, Soeda T, Matsumoto T, et al. Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies. J Thromb Haemost. 2018;16(7):1383–90.CrossRefPubMedGoogle Scholar
  42. 42.
    Nogami K, Matsumoto T, Tabuchi Y, et al. Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa/factor X bispecific antibody emicizumab. J Thromb Haemost. 2018;16(6):1078–88.CrossRefPubMedGoogle Scholar
  43. 43.
    Adamkewicz J, Kim B, Steinbuesch D, et al. Measurement of FVIII inhibitor titer using a chromogenic Bethesda assay (CBA) in the presence of emicizumab (ACE910), a humanized bispecific antibody mimicking FVIIIa cofactor function [abstract]. Haemophilia. 2017;23(Suppl 3):3–4.Google Scholar
  44. 44.
    Adamkewicz J, Chen DC, Paz-Priel I. Effects and interferences of emicizumab, a humanised bispecific antibody mimicking activated factor VIII cofactor function, on coagulation assays. Thromb Haemost. 2019;119:1084–93.CrossRefPubMedGoogle Scholar
  45. 45.
    US National Institutes of Health (2019) http://www.clinicaltrials.gov. Accessed 9 Sept 2019
  46. 46.
    Cafuir L, Kruse-Jarres R, Mancuso ME, et al. Emicizumab for hemophilia A without inhibitors. Expert Rev Hematol. 2019;12(7):515–24.CrossRefPubMedGoogle Scholar
  47. 47.
    Escuriola-Ettingshausen C, Sidonio RF Jr, Oldenburg J, et al. Modern treatment of inhibitor-positive patients with haemophilia A (MOTIVATE)—an international observational study [abstract no. PB1406]. Res Pract Thromb Haemost. 2019;3(Suppl 1):423.Google Scholar
  48. 48.
    Chen SL. Economic costs of hemophilia and the impact of prophylactic treatment on patient management. Am J Manag Care. 2016;22(Suppl 5):s126–33.PubMedGoogle Scholar
  49. 49.
    Institute for Clinical and Economic Review. Emicizumab for hemophilia A with inhibitors: effectiveness and value. 2018. http://icer-review.org/wp-content/uploads/2017/08/ICER_Hemophilia_Final_Evidence_Report_041618.pdf. Accessed 9 Sept 2019.
  50. 50.
    Mahajerin A, Zhou ZY, Raimundo K, et al. Model of short and long-term outcomes of emicizumab prophylaxis treatment for persons with hemophilia A [abstract]. Blood. 2018;132(Suppl 1):3511.CrossRefGoogle Scholar
  51. 51.
    Sidonio RF, Patel A, Corman S, et al. Model of the impact of delayed inhibitor development on cumulative breakthrough bleeds and costs in persons with hemophilia a receiving emicizumab prophylaxis [abstract]. Blood. 2018;132(Suppl 1):4710.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Springer NatureAucklandNew Zealand

Personalised recommendations